body composition is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-23. Numbers and descriptions here follow the published literature rather than marketing material.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
==== Companion of the Order of the Bath (CB) ==== Military Rear Admiral Andrew Betton, , Royal Navy, C033663C. Rear Admiral James David Morley, Royal Navy, C034410Y Major General Kevin Mark Copsey, , 533047. Major General John Robert Mead, , 537468. Air Vice-Marshal Nigel James Colman, , Royal Air Force, 8304546T. Air Marshal Ian David Gale, , Royal Air Force, 8304212Q. Civil Ruth Léonie Hannant, Director General, Policy, Department for Culture, Media and Sport. For Public Service. Liam Cledwyn Laurence Smyth, Clerk of Legislation, House of Commons. For services to Parliament. Jonathan Marron, Director General, Office of Health Inequalities and Disparities, Department of Health and Social Care. For services to Public Health. Lee McDonough, Director General, Net Zero, Nuclear and International, Department for Energy Security and Net Zero. For services to Energy and Climate. Simon Millhouse, Ministry of Defence. For services to Defence. Neil Brendan O'Connor, , lately Director, Building Safety Programme, Department for Levelling Up, Housing and Communities. For services to Building Safety. Polly Theresa Payne, Director General, Policy, Department for Culture, Media and Sport. For Public Service. Sir Arthur Gareth Ludovic Emrys Rhys Williams, , Government Chief Commercial Officer, Cabinet Office. For Public Service. Kenneth Andrew Lyons Thomson, lately Director General, Scottish Government. For Public Service. Brendan Peter Threlfall, , Director General, Union and Windsor Framework, Cabinet Office. For Public Service. Dr Abigail Tierney, lately Director General, Home Office.
For example, in Florida, a MLT may only perform highly complex testing while under the direct supervision of a clinical laboratory technologist, a clinical laboratory supervisor, or a clinical laboratory director. This may make it impractical for a MLT to lawfully work in a Florida blood bank. California has similar restrictions on MLTs. To accommodate California's restrictions, the American Association of Bioanalysts (AAB) developed a separate certification examination for California licensure. However, this exam does not include material covering the areas of immunohematology or microscopy. Although the typical entry-level academic requirement for most MLTs is an associate degree, a 60 credit certificate program exists through military training programs; such as the U.S. Army's 68K military occupational specialty. As in other countries, staffing shortages have become a major issue in many clinical laboratories in the United States. Due to several factors, including boomer retirement, and inadequate recruitment and retention efforts, the medical laboratory workforce is shrinking. For the decade 2010–2020, workforce needs are expected to grow by 13%. This translates into about 11,300 positions per year that will need to be filled, with only about 5000 new graduates per year coming out of various programs. It was estimated that the shortage of medical laboratory professionals would reach 98,700 in the U.S. by 2025.
Salvinorin A is one of several structurally related salvinorins found in the Salvia divinorum plant. Salvinorin A is the only naturally occurring salvinorin that is known to be psychoactive. Salvinorin A can be synthesized from salvinorin B by acetylation, and de-acetylated salvinorin A becomes analog to salvinorin B. Research has produced a number of semi-synthetic compounds. Most derivatives are selective kappa opioid agonists as with salvinorin A, although some are even more potent, with the most potent compound salvinorin B ethoxymethyl ether being ten times stronger than salvinorin A. Some derivatives, such as herkinorin, reduce kappa opioid action and instead act as mu opioid agonists. The synthetic derivative RB-64 is notable because of its functional selectivity and potency. Salvinorin B methoxymethyl ether is seven times more potent than salvinorin A at KOPr in GTP-γS assays.
== Connection and treatment of autism == Effective therapies to manage autism remain scarce. According to the exorphin theory of autism, an increase in the levels of exorphin is linked to symptoms of autism. Based on this concept, experiments have attempted to reduce the symptoms of autism by using large amounts of protease to break down exorphins before they are absorbed. Experiments have also attempted to enhance and utilize enzymes existing in the gut to break down exorphins in a similar fashion, since the production of exorphins within the gut is inevitable.
CP, Crude protein; NRC MR, National Research Council Minimal Requirement; NR, not required (taurine not an essential amino acid in the dog); NA, not adequate sample for analysis Amino acids measured on a mg/g DM basis The results demonstrated that all evaluated insects met the canine and feline MR for growth of the NRC for EAA and CP with exception to the black soldier fly in regards to taurine, where composition was lower than recommended.
Sources: en.wikipedia.org
Pocket watch movements are occasionally engraved with the word "Adjusted", or "Adjusted to n positions". This means that the watch has been tuned to keep time under various positions and conditions. There are eight possible adjustments:
As of 2013, 19,400 people inhabited the Kuril Islands, of which 16,700 lived on the four disputed southern islands and 2,600 lived on Paramushir, the northernmost large island; the islands in between are uninhabited. These include ethnic Russians, Ukrainians, Belarusians, Tatars, Nivkhs, Oroch, Japanese and Ainus. Russian Orthodox Christianity is the main religion. Some of the villages are permanently occupied by Russian soldiers. Others are inhabited by civilians, who are mostly fishermen, workers in fish factories, dockers, and social sphere workers (police, medics, teachers, etc.). Construction works on the islands have attracted migrant workers from the rest of Russia and other post-Soviet states. As of 2014, there were only 8 inhabited islands out of a total of 56.
Protein microarrays and high throughput (HT) mass spectrometry (MS) can provide a snapshot of the proteins present in a biological sample. The former approach faces similar problems as with microarrays targeted at mRNA, the latter involves the problem of matching large amounts of mass data against predicted masses from protein sequence databases, and the complicated statistical analysis of samples when multiple incomplete peptides from each protein are detected. Cellular protein localization in a tissue context can be achieved through affinity proteomics displayed as spatial data based on immunohistochemistry and tissue microarrays.
== Transmutation of technetium to stable ruthenium-100 == Technetium (Tc) can be completely transformed into ruthenium-100 by coating the inner cladding of fuel rods with Tc. This works with conventional pressurized water reactors and does not require specialized transmutation facilities. An alternative disposal method, transmutation, has been demonstrated at CERN and NIIAR for technetium-99. This transmutation process bombards the technetium (99Tc as a metal target) with neutrons, forming the short-lived 100Tc (half-life 16 seconds), which decays by beta decay to stable ruthenium (100Ru). Given the relatively high market value of ruthenium and the particularly undesirable properties of technetium, this type of nuclear transmutation appears particularly promising.
Sources: en.wikipedia.org
Pyruvate is taken up by a specific, low Km transporter to bring it into the mitochondrial matrix for oxidation by the pyruvate dehydrogenase complex. The phosphate carrier (PiC) mediates the electroneutral exchange (antiport) of phosphate (H2PO−4; Pi) for OH− or symport of phosphate and protons (H+) across the inner membrane, and the driving force for moving phosphate ions into the mitochondria is the proton motive force. The ATP-ADP translocase (also called adenine nucleotide translocase, ANT) is an antiporter and exchanges ADP and ATP across the inner membrane. The driving force is due to the ATP (−4) having a more negative charge than the ADP (−3), and thus it dissipates some of the electrical component of the proton electrochemical gradient. The outcome of these transport processes using the proton electrochemical gradient is that more than 3 H+ are needed to make 1 ATP. Obviously, this reduces the theoretical efficiency of the whole process and the likely maximum is closer to 28–30 ATP molecules. In practice the efficiency may be even lower because the inner membrane of the mitochondria is slightly leaky to protons. Other factors may also dissipate the proton gradient creating an apparently leaky mitochondria. An uncoupling protein known as thermogenin is expressed in some cell types and is a channel that can transport protons. When this protein is active in the inner membrane it short circuits the coupling between the electron transport chain and ATP synthesis. The potential energy from the proton gradient is not used to make ATP but generates heat.
== Professional affiliations == Beavis was a founding member of Genome Prairie and one of the founders of ProteoMetrics, LLC. He has held academic positions at Rockefeller University, Memorial University of Newfoundland and Labrador, New York University Medical Center, the University of British Columbia and the University of Manitoba. He served on the Editorial Advisory Boards of the Journal of Proteome Research and Rapid Communications in Mass Spectrometry. He has also served on the Editorial Board of Molecular & Cellular Proteomics and on the Editorial Board of Scientific Data. He was part of the Human Proteome Project and a founding member of the U.S. Chromosome 17 project. He has frequently collaborated with David Fenyő on informatics projects.
=== Application === Among these four moisture conditions of aggregates, saturated surface dry is the condition that has the most applications in laboratory experiments, research, and studies, especially those related to water absorption, composition ratio, or shrinkage tests in materials like concrete. For many related experiments, a saturated surface dry condition is a premise that must be realized before the experiment. In saturated surface dry conditions, the aggregate's water content is in a relatively stable and static situation where its environment would not affect it. Therefore, in experiments and tests where aggregates are in saturated surface dry condition, there would be fewer disrupting factors than in the other three conditions.
== Function == This gene is a member of the Insulin-like growth factor-binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a type-I thyroglobulin domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
Peptidyl-glycine alpha-amidating monooxygenase, or PAM, is an enzyme that catalyzes the conversion of an n+1 residue long peptide with a C-terminal glycine into an n-residue peptide with a terminal amide group. In the process, one molecule of O2 is consumed and the glycine residue is removed from the peptide and converted to glyoxylic acid. The enzyme is involved in the biosynthesis of many signaling peptides and some fatty acid amides. In humans, the enzyme is encoded by the PAM gene. This transformation is achieved by conversion of a prohormone to the corresponding amide (C(=O)NH2). This enzyme is the only known pathway for generating peptide amides. Replacing the carboxylic acid group with an amide group makes the peptide more hydrophobic and more likely to be neutrally charged at physiologic pH, and it is believed that these neutrally charged peptide amides can more easily bind to receptors.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.